TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38761811
Drug: Best medical
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best medical treatment alone
Study: 34118115
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg DPV ring
Study: 34118115
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg DPV ring
Study: 34118115
Drug: Monthly 25
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly 25 mg DPV ring
Study: 34344273
Drug: Standardized educational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized educational intervention on cancer pain management and analgesics (10-15 minutes)
Study: 35395427
Drug: Curative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curative treatment (n = 78)
Study: 35395427
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment (17 patients)
Study: 35395427
Drug: RCT comparing
Approvals — FDA: no, EMA: no, PMDA: no
Description: RCT comparing endovascular with surgical treatment (20 patients)
Study: 33181169
Drug: Transcutaneous application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous application of gaseous CO2 (CO2 therapy) for 4 weeks
Study: 33181169
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment with transcutaneous application of air for 4 weeks
Study: 35057599
Drug: Tofacitinib (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib (10 mg for 14 days)
Study: 35057599
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care (SOC) treatment alone
Study: 32134320
Drug: weekly written
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: weekly written feedback individualized by a counselor
Study: 35486012
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (eye acupuncture + exercise therapy)
Study: 33561963
Drug: Monthly high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly high-dose vitamin D supplementation (initial dose of 200,000 IU vitamin D3 followed by 100,000 IU monthly)
Study: 38743288
Drug: Monthly high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly high-dose vitamin D supplementation
Study: 32151236
Drug: Robotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robotic therapy (ReoGeo system) plus standard therapy
Study: 32151236
Drug: Self-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-guided therapy plus standard therapy
Study: 35074433
Drug: DWI-guided dose-painting
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWI-guided dose-painting intensity modulated radiation therapy (DP-IMRT)
Study: 34292204
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of oral naltrexone (n = 42)
Study: 33098212
Drug: Standard pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard pump therapy with CGM initiation delayed for 6 months
Study: 39714936
Drug: Hybrid closed-loop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid closed-loop insulin delivery
Study: 33275819
Drug: Selegiline and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline and symptomatic treatment for iRBD
Study: 35150818
Drug: Barberry group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barberry group (10 g/day dried purple-black barberry powder, once daily for 2 months)
Study: 32969197
Drug: Lifestyle intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lifestyle intervention (LS) with cognitive behavioral therapy, nutrition advice, and exercise
Study: 32969197
Drug: Lifestyle intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lifestyle intervention (LS) with cognitive behavioral therapy, nutrition advice, exercise, and SMS
Study: 35780511
Drug: Treatment completers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment completers
Study: 38682335
Drug: No lipid-lowering
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: No lipid-lowering therapy
Study: 33962565
Drug: Dexmedetomidine (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (loading dose 0.6 µg/kg in 10 min before anaesthesia induction, followed by continuous infusion 0.5 µg/kg/hr until 1 hour before end of surgery)
Study: 32558989
Drug: Danicamtiv (50–100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danicamtiv (50–100 mg twice daily for 7 days)
Study: 35578822
Drug: Stabilized hypochlorous
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stabilized hypochlorous acid solution
Study: 35578822
Drug: Control (sterile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (sterile 0.9% NaCl) solution
Study: 35034017
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy (CCRT) with adjuvant chemotherapy (AC)
Study: 35034017
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy (CCRT) without adjuvant chemotherapy (AC)
Study: 33942566
Drug: PN-943, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: PN-943, 100 to 1400 mg (single doses)
Study: 33942566
Drug: PN-943, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: PN-943, 100 to 1000 mg (multiple doses)
Study: 33942566
Drug: 450 mg
Normalized name: aspirin 450 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 mg PN-943 (twice daily)
Study: 33942566
Drug: PN-943 (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: PN-943 (multiple doses)
Study: 33942566
Drug: PN-943 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: PN-943 (single and multiple doses)
Study: 32044319
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg upadacitinib twice daily
Study: 32044319
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg upadacitinib twice daily
Study: 32044319
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg upadacitinib twice daily
Study: 32044319
Drug: 24 mg
Normalized name: uracil 224 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 mg upadacitinib twice daily
Study: 32044319
Drug: 24 mg
Normalized name: uracil 224 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 mg upadacitinib once daily
Study: 36934327
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (CONV)
Study: 32687741
Drug: Prasugrel (reduced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (reduced dose in elderly or low-weight group)
Study: 32687741
Drug: Ticagrelor (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (standard dose)
Study: 32687741
Drug: Prasugrel (reduced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (reduced dose in neither elderly nor low-weight group)
Study: 34413118
Drug: Insulin icodec
Normalized name: insulin icodec
DrugBank: Insulin icodec (DB16693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin icodec
Study: 35710576
Drug: bDMARD tapering
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bDMARD tapering according to a strategy that combines disease activity guided dose optimization (DGDO) with a dynamic flare prediction model.
Study: 35710576
Drug: disease activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: disease activity guided dose optimization (DGDO)
Study: 35710576
Drug: bDMARD tapering
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bDMARD tapering according to a strategy that combines DGDO with the dynamic flare prediction model.
Study: 33648940
Drug: Polyphenon E
Normalized name: Polyphenon E
DrugBank: Sinecatechins (DB01266)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polyphenon E (780 mg EGCG daily for 6 months)
Study: 32677772
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (diphereline) at two doses, 8 weeks before endometrial preparation
Study: 32677772
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with estradiol valerate (6-8 mg/day)
Study: 32677772
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (diphereline)
Study: 33309349
Drug: Flunixin meglumine
Normalized name: Flunixin Meglumine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunixin meglumine (FLU) 2.2 mg/kg i.v. and whey protein placebo orally
Study: 33309349
Drug: Meloxicam (MEL)
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meloxicam (MEL) 1 mg/kg orally and 2 mL/45 kg sterile saline placebo i.v.
Study: 34911681
Drug: Nivolumab 240
Normalized name: nivolumab 240 MG in 24 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 240 mg intravenously on days 1 and 15 + Tadalafil 10 mg orally once daily for 4 weeks
Study: 33344227
Drug: Nivolumab 240
Normalized name: nivolumab 240 MG in 24 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 240 mg intravenously on days 1 and 15
Study: 34669179
Drug: Sonidegib 200
Normalized name: sonidegib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sonidegib 200 mg once daily
Study: 33347567
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplementation of 10 μg daily from age 2 weeks to 2 years
Study: 33347567
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplementation of 30 μg daily from age 2 weeks to 2 years
Study: 33347567
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of group 30 (30 μg) vs group 10 (10 μg)
Study: 33347567
Drug: Highest quartile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highest quartile of 25(OH)D (> 121 nmol/L)
Study: 36138362
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with immunotherapy
Study: 35322373
Drug: G-CSF plus
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF plus standard medical therapy
Study: 35322373
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus standard medical therapy
Study: 35122371
Drug: Intravenous thrombolysis
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thrombolysis (IVT) alone
Study: 32474650
Drug: Teriparatide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide (20 μg subcutaneous daily)
Study: 32474650
Drug: Risedronate (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate (35 mg oral weekly)
Study: 33739197
Drug: Control (medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (medical therapy alone)
Study: 33091344
Drug: Flexible assertive
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexible assertive community treatment (FACT)
Study: 35732397
Drug: mHealth application
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: mHealth application for treatment support
Study: 32623928
Drug: Bleomycin‐containing combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bleomycin‐containing combination chemotherapy regimen
Study: 33188552
Drug: Bergamot phytosome
Normalized name: BERGAMOT
DrugBank: Bergamot oil (DB14335)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bergamot phytosome (500 mg, two daily tablets)
Study: 33188552
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two daily tablets)
Study: 36195936
Drug: Radiofrequency microtenotomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiofrequency microtenotomy treatment, patient education, and a heel insert
Study: 33940563
Drug: Agomelatine in
Normalized name: Product containing agomelatine in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agomelatine in combination with conventional cerebrovascular disease medication
Study: 33940563
Drug: Sertraline in
Normalized name: Product containing sertraline in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline in combination with conventional cerebrovascular disease medication
Study: 33940563
Drug: Escitalopram in
Normalized name: Product containing escitalopram in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram in combination with conventional cerebrovascular disease medication
Study: 33940563
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment alone (Control group)
Study: 39587796
Drug: Lansoprazole (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (30 mg)
Study: 36235553
Drug: Insulin levels
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin levels at 4 months
Study: 39374130
Drug: Individualized Assessment
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized Assessment and Treatment Program (IATP)
Study: 34014689
Drug: Conventional motivational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional motivational enhancement + cognitive-behavioral treatment (MET-CBT)
Study: 32341121
Drug: Tolcapone (COMT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolcapone (COMT inhibitor)
Study: 32862453
Drug: Micronutrient powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient powder containing 12 mg iron for 12 weeks
Study: 33581820
Drug: tE2 patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: tE2 patches (four 100 μg patches per 24 h, changed twice weekly)
Study: 33581820
Drug: tE2 patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: tE2 patches
Study: 32182364
Drug: Follow-up after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow-up after treatment
Study: 33928797
Drug: GP40071 insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: GP40071 insulin aspart (GP‐Asp)
Study: 35413921
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care plus icatibant (30 mg subcutaneously 3 times a day for 3 days)
Study: 32638445
Drug: Cinnamon powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnamon powder (three capsules/day each containing 600 mg of cinnamon)
Study: 32638445
Drug: Placebo (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (three capsules/day each containing 100 mg of corn starch)
Study: 33906807
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL PRP intracavernosal injections, n = 30
Study: 33906807
Drug: Placebo intracavernosal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intracavernosal injections, n = 30
Study: 32601289
Drug: Mustard aphid
Normalized name: MUSTARD
DrugBank: White mustard seed (DB15606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mustard aphid (L. erysimi)
Study: 33894153
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 600,000 IU of vitamin D3
Study: 32883721
Drug: Internet-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based intervention based on Acceptance and Commitment Therapy (ACT), 7 modules over 7 weeks, guided by a trained e-coach.
Study: 32883721
Drug: Internet-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based intervention based on Acceptance and Commitment Therapy (ACT)
Study: 33069664
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg caffeine
Study: 34257088
Drug: Structured pharmacotherapy
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured pharmacotherapy optimisation intervention
Study: 34197339
Drug: Homeopathic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathic treatment (Berberis 6CH, Mercurius Solubilis/Belladona/Hepar Sulfur, Pyrogenium 200CH biotherapic) prescribed in diluted low ultra-diluted concentration doses for all signs and symptoms, with biotherapics used for chronic stimulation.
Study: 34197339
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Conventional periodontal therapy without homeopathy)
Study: 33153828
Drug: Quetiapine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (300 mg nightly)
Study: 36062743
Drug: Netakimab (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Netakimab (120 mg subcutaneous at weeks 0, 1, 2, and every other week thereafter)
Study: 33036921
Drug: Pentoxifylline 400
Normalized name: pentoxifylline 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline 400 mg, three times daily, for 9 doses within 72 hours of diagnosis
Study: 36229048
Drug: Otilimab 90
Normalized name: Otilimab
DrugBank: Otilimab (DB06303)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Otilimab 90 mg plus standard care
Study: 32376815
Drug: Normal daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal daily activities for 8 weeks
Study: 34563635
Drug: Standard parotid-sparing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard parotid-sparing radiation therapy
Study: 34563635
Drug: Stem cell
Normalized name: Stem cells, apheresis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stem cell sparing (SCS) radiation therapy
Study: 34196379
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL suction
Study: 34196379
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL suction
Study: 34898293
Drug: Menopausal hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Menopausal hormone therapy (MHT) with exercise and education
Study: 35608484
Drug: Liberal approach
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal approach to glucose control (IV insulin commenced at blood glucose >252 mg/dl, titrated to 180-252 mg/dl)
Study: 35608484
Drug: Control approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control approach to glucose control (IV insulin commenced at blood glucose >180 mg/dl, titrated to 108-180 mg/dl)
Study: 34022750
Drug: Topical capsaicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical capsaicin (0.075%)
Study: 33288086
Drug: Tazarotene 0.05%
Normalized name: TAZAROTENE 0.05% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tazarotene 0.05% gel with NB-UVB
Study: 36370871
Drug: Relugolix combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relugolix combination therapy (40 mg relugolix, 1 mg estradiol, and 0.5 mg norethindrone acetate once daily)
Study: 39466126
Drug: Relugolix combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relugolix combination therapy
Study: 33591141
Drug: SA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: SA with morphine 0.1 mg (SA0.1)
Study: 33591141
Drug: SA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: SA with morphine 0.2 mg (SA0.2)
Study: 33591141
Drug: Fascia iliaca
Normalized name: OCTINOXATE .012 mL in 6 mL / OCTISALATE .12 mL in 6 mL TOPICAL CREAM [RIMMEL LONDON MOISTURE RENEW LIPGLOSS - FUSCIA THERAPHY (345)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fascia iliaca compartment block with dexamethasone 4 mg + levobupivacaine 0.375% 20 mL (FICB20)
Study: 33591141
Drug: Fascia iliaca
Normalized name: OCTINOXATE .012 mL in 6 mL / OCTISALATE .12 mL in 6 mL TOPICAL CREAM [RIMMEL LONDON MOISTURE RENEW LIPGLOSS - FUSCIA THERAPHY (345)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fascia iliaca compartment block with dexamethasone 4 mg + levobupivacaine 0.375% 30 mL (FICB30)
Study: 33591141
Drug: Lateral femoral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lateral femoral cutaneous nerve block with levobupivacaine 0.25% 5 mL (LFCNB)
Study: 33591141
Drug: Standardized analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized analgesia (intravenous metamizole magnesium, dexketoprofen, paracetamol, morphine, regional rescue)
Study: 32771596
Drug: Nonresponders to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonresponders to mesh removal treatment.
Study: 34964149
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg galantamine (acute administration)
Study: 35725017
Drug: Postpartum diabetes
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postpartum diabetes screening (2-hour oral glucose tolerance test within 4-12 weeks postpartum)
Study: 32320465
Drug: Ad26.RSV.preF low-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad26.RSV.preF low-dose (LD; 5 × 10^10 vector particles)
Study: 32320465
Drug: Ad26.RSV.preF high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad26.RSV.preF high-dose (HD; 1 × 10^11 vector particles)
Study: 35781888
Drug: 3-day protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day protocol of systemic antibiotics (amoxicillin and metronidazole) 500mg 3-times-daily for 3 days, followed by placebo 3-times-daily for 4 days
Study: 35781888
Drug: 7-day protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day protocol of systemic antibiotics (amoxicillin and metronidazole) 500mg 3-times-daily for 7 days
Study: 33176232
Drug: Pertuzumab (first-line
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pertuzumab (first-line therapy)
Study: 33176232
Drug: Trastuzumab–taxane (first-line
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab–taxane (first-line therapy)
Study: 35299035
Drug: T-DM1 (second-line
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-DM1 (second-line treatment)
Study: 33176232
Drug: First-line treatment
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line treatment for mBC